{"nctId":"NCT00747344","briefTitle":"A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis","startDateStruct":{"date":"2008-12"},"conditions":["Psoriasis"],"count":121,"armGroups":[{"label":"Placebo - Controlled Period (CP)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo - Controlled Period (CP)"]},{"label":"Ustekinumab 45 mg - CP","type":"EXPERIMENTAL","interventionNames":["Drug: Ustekinumab 45 mg - CP"]},{"label":"Placebo to ustekinumab 45 mg - after CP","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo to ustekinumab 45 mg - after CP"]},{"label":"Ustekinumab 45 mg - after CP","type":"EXPERIMENTAL","interventionNames":["Drug: Ustekinumab 45 mg - after CP"]}],"interventions":[{"name":"Placebo - Controlled Period (CP)","otherNames":[]},{"name":"Ustekinumab 45 mg - CP","otherNames":[]},{"name":"Placebo to ustekinumab 45 mg - after CP","otherNames":[]},{"name":"Ustekinumab 45 mg - after CP","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be of Taiwanese or Korean ancestry living in Taiwan or South Korea, respectively\n* Have a diagnosis of plaque-type psoriasis at least 6 months prior to first administration of study agent (patients with concurrent psoriatic arthritis may be enrolled)\n* Have plaque-type psoriasis covering at least 10% of total body surface area at screening and at the time of first study agent administration\n* PASI score of 12 or greater at the time of screening and at time of first study agent administration\n* Candidate of phototherapy or systemic treatment of psoriasis (either na√Øve or history of previous treatment)\n* Be able to adhere to the study visit schedule and other protocol requirements\n* Capable of giving informed consent prior to any study related procedures.\n\nExclusion Criteria:\n\n* Currently have a non-plaque form of psoriasis\n* Have current drug-induced psoriasis\n* Are pregnant or nursing or planning pregnancy (both men and women) while enrolled in the study\n* Have used any investigational drug within the previous 4 weeks or 5 times the half life of the investigational agent, whichever is longer\n* Have used any biologic within the previous 3 months or 5 times the half life of the biologic, whichever is longer\n* Have been hospitalized in the past 3 years for asthma, ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or required more than one short-term course of oral corticosteroids for asthma within the previous year\n* Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis prior to screening.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) at Week 12","description":"PASI score can range from 0 (no psoriasis) to 72 (severe psoriasis).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Patients With a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in Dermatology Life Quality Index (DLQI) From Baseline at Week 12","description":"Scores could range from 0 to 30. A lower DLQI score represents better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"6.51"},{"groupId":"OG001","value":"-11.2","spread":"7.07"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":60},"commonTop":["Pruritus","Upper respiratory tract infection","Nasopharyngitis","Hyperglycaemia","Psoriasis"]}}}